Treatment Challenges in a Patient with Diastolic-Predominant Hypertension and Suspected Antihypertensive Adverse Effects: A Case Report

Background and Clinical Significance: Hypertension management can be challenging when suspected adverse drug reactions limit conventional treatment. This case shows how a sequence of treatment changes in a patient with diastolic-predominant office blood pressure elevation and asthma becomes difficult to interpret when out-of-office, rhythm and safety documentation is incomplete. Case Presentation: A 41-year-old man with moderate persistent asthma had office blood pressure averaging approximately 135/95 mmHg and a resting heart rate of 92 bpm, persisting after two months of lifestyle intervention. Ambulatory monitoring was not performed, and home readings were unavailable. Nebivolol, hydrochlorothiazide and perindopril were followed by patient-reported nightmares, somnolence and erectile dysfunction, and nebivolol was stopped. Verapamil was then added, followed by a reported heart rate of 120–130 bpm of undetermined rhythm (no electrocardiogramor rhythm recording), and was stopped. After a limited endocrine evaluation that could not exclude primary aldosteronism, spironolactone and off-label ivabradine (first documented dose 7.5 mg twice daily, the maximum maintenance dose) were added to perindopril and hydrochlorothiazide, with office blood pressure of approximately 120/80 mmHg. Phosphenes occurred, and gynecomastia later prompted a switch to eplerenone; subsequent measurements, biochemistry and outcome were unavailable. Conclusions: The principal problem was treatment tolerability, not confirmed resistant hypertension. The report is a descriptive account of tolerability-driven treatment changes. The missing documentation limits assessment of the indication for escalation, the heart-rate episode, biochemical safety and the final outcome. It does not establish the contribution or necessity of any individual medication, and it should not be read as support for a multidrug strategy or for off-label ivabradine.

Authors

Institutions

Publication Details

Journal
Reports — Medical Cases Images and Videos
Published
2026-11-19
DOI
https://doi.org/10.3390/reports9040400
Primary Topic
Blood Pressure and Hypertension Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Treatment Challenges in a Patient with Diastolic-Predominant Hypertension and Suspected Antihypertensive Adverse Effects: A Case Report

H. Zlatanova, Spas Ivanov Kitov
Reports — Medical Cases Images and Videos
Blood Pressure and Hypertension Studies
article

Treatment Challenges in a Patient with Diastolic-Predominant Hypertension and Suspected Antihypertensive Adverse Effects: A Case Report

H. Zlatanova, Spas Ivanov Kitov
article en

Abstract

Background and Clinical Significance: Hypertension management can be challenging when suspected adverse drug reactions limit conventional treatment. This case shows how a sequence of treatment changes in a patient with diastolic-predominant office blood pressure elevation and asthma becomes difficult to interpret when out-of-office, rhythm and safety documentation is incomplete. Case Presentation: A 41-year-old man with moderate persistent asthma had office blood pressure averaging approximately 135/95 mmHg and a resting heart rate of 92 bpm, persisting after two months of lifestyle intervention. Ambulatory monitoring was not performed, and home readings were unavailable. Nebivolol, hydrochlorothiazide and perindopril were followed by patient-reported nightmares, somnolence and erectile dysfunction, and nebivolol was stopped. Verapamil was then added, followed by a reported heart rate of 120–130 bpm of undetermined rhythm (no electrocardiogramor rhythm recording), and was stopped. After a limited endocrine evaluation that could not exclude primary aldosteronism, spironolactone and off-label ivabradine (first documented dose 7.5 mg twice daily, the maximum maintenance dose) were added to perindopril and hydrochlorothiazide, with office blood pressure of approximately 120/80 mmHg. Phosphenes occurred, and gynecomastia later prompted a switch to eplerenone; subsequent measurements, biochemistry and outcome were unavailable. Conclusions: The principal problem was treatment tolerability, not confirmed resistant hypertension. The report is a descriptive account of tolerability-driven treatment changes. The missing documentation limits assessment of the indication for escalation, the heart-rate episode, biochemical safety and the final outcome. It does not establish the contribution or necessity of any individual medication, and it should not be read as support for a multidrug strategy or for off-label ivabradine.

Reports — Medical Cases Images and VideosVol. 9(4)
Medical University Plovdiv (BG), University Multipurpose Hospital for Active Treatment "Sveti Georgi" (BG)
Blood Pressure and Hypertension Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon